Abstract:Porcine circovirus type 2 (PCV2) is one of the most serious pathogens in pig herds worldwide. The Capsid protein (Cap), a structural protein of PCV2, is involved in the host's immune response; it induces neutralizing-antibody production and has good immunogenicity. The main PCV2 subtype currently prevalent in the Chinese pig herd is PCV2d. In this study, We constructed a recombinant Bacillus subtilis (B. subtilis) capable of secreting Cap protein, named pHT43-Cap/B. subtilis; we concentrated the supernatant of the recombinant bacteria and observed virus-like particles (VLPs) of PCV2d formed by Cap protein under transmission electron microscopy, named PCV2d-VLPs. The immunocompetence of the pHT43-Cap/B. subtilis and PCV2d-VLPs were then assessed by oral administration and by intramuscular injection into mice, respectively. The results showed that the levels of PCV2d-Cap protein-specific IgG in the serum and of PCV2d-Cap protein-specific sIgA in the small intestinal fluid of pHT43-Cap/B. subtilis immunized mice were elevated compared to the control group, both of them highly significant (p < 0.01), and the corresponding serum-specific IgG antibodies were effective in neutralizing PCV2d virulence. The virus load in the liver of the immunized mice was significantly lower than that in the control group (p < 0.01), as was the virus load in the spleen and lungs of the immunized mice (p < 0.05). In addition, the serum levels of PCV2d-Cap-specific IgG in mice immunized with PCV2d-VLPs by intramuscular injection were significantly elevated compared to the control group (p < 0.05), and the viral load in all tissues was significantly lower in immunized mice (p < 0.05). In conclusion, the recombinant bacterium pHT43-Cap/B. subtilis can induce effective mucosal and humoral immunity in mice, PCV2d-VLPs can induce humoral immunity in mice, and both vaccines have good immunogenicity; these results provide a theoretical and material basis for the development of a new vaccine against PCV2d.

Progress Toward the Development of a Vaccine Against Streptococcus Suis Capsular Type2

Progress Toward the Development of a Vaccine Against Streptococcus suis Capsular Type 2

Research Progress in China on the Virulence Factors of Streptococcus Suis Serotype

Genetic and Virulence Characterization of Streptococcus Suis Type 2 Isolates from Swine in the Provinces of Zhejiang and Henan, China

Development of a Universal Multi-Epitope Vaccine Candidate Against Streptococcus Suis Infections Using Immunoinformatics Approaches

TLR4 Agonist Combined with Trivalent Protein JointS of <i>Streptococcus suis</i> Provides Immunological Protection in Animals

Regulative synthesis of capsular polysaccharides in the pathogenesis of Streptococcus suis

Research Progress on the Pathogenic Mechanism of Meningitis Infected by Streptococcus Suis Serotype 2

Pan-genome analysis of Streptococcus suis serotype 2 highlights genes associated with virulence and antibiotic resistance

Combined Immunoinformatics to Design and Evaluate a Multi-Epitope Vaccine Candidate against Streptococcus suis Infection

Roles of the Putative Type IV-like Secretion System Key Component VirD4 and PrsA in Pathogenesis of Streptococcus Suis Type 2.

A multi-epitope subunit vaccine providing broad cross-protection against diverse serotypes of Streptococcus suis

Insight into the role of Streptococcus suis zinc metalloprotease C from the new serotype causing meningitis in piglets

Uncovering newly emerging variants of Streptococcus suis, an important zoonotic agent.

O-acetyl-homoserine Sulfhydrylase Deficient Streptococcus Suis Serotype 2 Strain SC19 Becomes an Avirulent Strain and Provides Immune Protection Against Homotype Infection in Mice

Immunogenicity and Protective Capacity of Sugar ABC Transporter Substrate-Binding Protein against Streptococcus suis Serotype 2, 7 and 9 Infection in Mice

Identification of E2 Strain with Improved Secretion and Immunogenicity Against CSFV in Piglets

Live attenuated Salmonella enterica serovar Choleraesuis vector delivering a conserved surface protein enolase induces high and broad protection against Streptococcus suis serotypes 2, 7, and 9 in mice

Both recombinant Bacillus subtilis Expressing PCV2d Cap protein and PCV2d-VLPs can stimulate strong protective immune responses in mice

Development of a Combined Genetic Engineering Vaccine for Porcine Circovirus Type 2 and Mycoplasma Hyopneumoniae by a Baculovirus Expression System

A Streptococcus suis Strain Δcps/ssna-msly (P353L)-SC19 Provides Cross-Protection against Serotypes 2 and 9 Strain Challenges in a Mouse Model